Dogwood Therapeutics Reports Interim Results For Halneuron In Chemotherapy-Induced Neuropathic Pain Study; Expects Top-Line Results Availability In Q3 2026

- Halneuron® treated patients separating from placebo on pain improvement assessment; Company expects top-line results availability in Q3 2026 -

- The overall study dropout rate of ~4.4% is far below rates typically observed with other FDA approved chronic pain medicines -

ATLANTA, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (NASDAQ:DWTX) (the "Company"), a development-stage biotechnology company developing new medicines to treat pain and neuropathy, today announces positive results from an interim analysis of 97 patients who had completed treatment in the ongoing Halneuron® Phase 2b chemotherapy induced neuropathic pain ("CINP") study. The independent statistical review committee reviewed unblinded patient treatment data from the Phase 2b trial and concluded that Halneuron® treated patients are demonstrating separation from placebo treated patients in terms of pain improvement over the four-week study.   

Based on the current Phase 2b trial enrollment pace and the interim assessment results, the Company continues to expect to have top-line results available during Q3 2026. Current study patient enrollment trends are projected to provide statistical power of approximately 80% to 85% to detect a Halneuron® treatment difference.